Abbvie announce phase 3 GLOW study of ibrutinib plus venetoclax combination shows superior progression-free survival (PFS) compared to chlorambucil plus obinutuzumab in first-line chronic lymphocytic leukaemia

The study (n=211) of this first all-oral, once-daily, chemotherapy-free, fixed-duration investigational combination met its primary endpoint of superior PFS, demonstrating a reduction in risk of disease progression or death of ~ 78% (HR 0.216; 95% CI, 0.131-0.357; p < 0.0001).

Biospace Inc.